Drug Trial Radar · NCT07018050
Phase II Study of QLS32015 Combination Therapy in the Treatment of Multiple Myeloma
Last checked: Nov 19, 2026Latest source record: Jun 8, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
160
Planned (sponsor's estimate)
Start
Sep 12, 2025
Primary completion
Nov 2027
Study completion Jul 2028
Sponsor
- Lead sponsor
- Qilu Pharmaceutical Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Jun 12, 2025
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of the study is to compare the efficacy of QLS32105 (SC) in combination with Pomalidomide, and QLS32105 (SC) in combination with QL2109 or Daratumumab, and QLS32105 (SC) in combination with QL2109 or Daratumumab and Pomalidomide, and QLS32105(SC) in combination with Bortezomib and Lenalidomide.
Conditions
- Relapsed or Refractory Multiple Myeloma
Interventions
QLS32015Drug
QLS32015 will be administered subcutaneously
PomalidomideDrug
Pomalidomide will be self-administered as a single dose orally
DexamethasoneDrug
Dexamethasone will be administered orally or intravenously
QL2109 or DaratumumabDrug
QL2109 or Daratumumab will be administered subcutaneously.
BortezomibDrug
Bortezomib will be administered subcutaneously
LenalidomideDrug
Lenalidomide will be self-administered as a single dose orally
Primary outcomes
What the sponsor says the trial is designed to measure.
- ORR (Partial Response [PR] or Better)Time frame: Up to 2 years
- Overall Minimal Residual Disease (MRD)Time frame: Up to 2 years
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Institute of Hematology & Blood Diseases Hospital
Tianjin, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.